|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The application and efficacy of stent place for Budd-Chiari syndrome显示文摘Objective To evaluate the application value and efficacy on stent place for Budd-Chiari syndrome(BCS). Methods From January 1990 to May 2017, 2228 patients with BCS were admitted to our institution. The mean age was 43.3 years. Stents were placed in inferior vena cava(IVC), hepatic vein(HV), or both after balloon dilation. During follow-up period, the patency of stent was evaluated by ultrasound regularly and the clinic sign was surveyed by letter, telephone or clinic visit. The restenosis of stent were treated with balloon dilatation and thrombolysis to restore the its function. Results IVC type was diagnosed in 1492 cases, HV type in 510 cases, and mixed type in 226 cases. Eighteen patients aborted treatment because of economic reasons, advanced liver cancer, severe scoliosis, or both bilateral iliac veins and total IVC occlusion. Among the other 2210 cases who underwent endovascular therapy, stents were implanted into IVC in 339 cases, HV in 97 cases, mixed type in 64 cases. The rate of restenosis in IVC stent was 11.50%(39/339). After repeat angioplasty, the long-term patency rate reached to 98.12%. The incidence of HV occlusion caused by IVC stent was 12.09%(n = 41). Restenosis occurred in 47 cases(48.45%) after HV stent placement. However, the 5-year patency rate was 91.75%(89/97) after repeat dilatation and stent re-implantation. The incidence of IVC obstruction caused by HV was 3.33%(3 cases). Conclusion IVC stent placement appears to be an effective treatment for the cases of IVC segmental occlusion, and at the same time, the stent has the dual role of compression and fixation of thrombus and support of lumen. The HV and accessory hepatic vein obstruction could happen when the IVC stent crossed these veins ostium. The incidence of the stent restenosis in the HV was higher than that in the IVC. | Maoheng Zu Hao Xu Yuming Gu Qingqiao Zhang Ning Wei Wei Xu Yanfeng Cui | 2018 | Journal of Interventional Medicine2018，1，3： | 7 |
| 2 | Experts consensus on Chinese nomenclature of Budd-Chiari syndrome显示文摘In China,Budd-Chiari syndrome has been transliterated into six names according to the pronunciation of the letters.To standardize and unify the Chinese names of the disease,multi-disciplinary experts suggest translating Budd-Chiari syndrome into hepatic vein inferior venal cava obstruction syndrome as its Chinese name after reaching a consensus through discussion. | Maoheng Zu Ke Xu Interventional Division of Radiology Society of Chinese Medical Association | 2021 | Journal of Interventional Medicine2021，4，3： | 4 |
| 3 | JAK 2 V 617 F mutation and 46/1 haplotype in C hinese B udd‐ C hiari syndrome patients显示文摘 | Hui Wang Guixiang Sun Peijin Zhang Jing Zhang Er Gui Maoheng Zu Enzhi Jia Hao Xu Lichun Xu Jinpeng Zhang Zhaojun Lu | 2014 | J Gastroenterol Hepatol2014，，1： | 1 |
| 4 | Phthalimide and Naphthalimide end-Capped Diketopyrrolopyrrole for Organic Photovoltaic Applications显示文摘二个小分子作为终端作为中央强壮的领受人单位和 phthalimide/naphthalimide 与一个 DPP 核心说出 PI-DPP 和 NI-DPP 弱领受人被设计并且综合。热行为,光、电气化学的性质,以及这二材料的光电的表演上的终端 phthalimide/naphthalimide 单位的效果系统地被学习。周期的 voltammetry 表明两个分子的最低没有住的分子的 orbitals (LUMO )(^-3.6 eV ) 对普通电子施主(P3HT ) 和领受人(PCBM ) 中间。当与 PCBM 相配时,当与 P3HT 相配时,在在 DPP 和 PCBM 之间,以及在 P3HT 和 DPP 之间的足够的驱动力应该为激子分离被创造的地方,这显示 PI-DPP 和 NI-DPP 可以特别地用作电子施主,并且作为电子领受人。用作电子施主材料, PI-DPP 和 NI-DPP 设备由分别地与 PCBM 相配展出了 0.90% 和 0.76% 的低力量变换效率(PCE ) 。并且 NI-DPP 的潜力的初步的评估作为施主材料,和 P3HT 用 P3HT 作为电子领受人材料被执行: NI-DPP 设备显示出0.6%的 PCE ,与开的电路电压( V 0.7 V 的 OC ),短路电流密度( J 1.91 mAcm -2,和45%的一个fill 因素( FF )的 SC )。 | Ming Chen Chenchen Du Xiaolei Ren Maoheng Yi Jinduo Yi Chufeng Chen Feng Liu Minjie Li Changqi Ma Hongyu Wang | 2017 | Chinese Journal of Chemistry2017，35，9： | 1 |
| 5 | Risk factors of recurrence among 471 Chinese patients with Budd-Chiari syndrome显示文摘 | Xiuyin Gao Er Gui Zhaojun Lu Xin Ning Maoheng Zu Peijin Zhang Guixiang Sun | 2015 | Clinics and Research in Hepatology and Gastroente2015，，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员